{"id":68340,"date":"2026-06-16T22:44:33","date_gmt":"2026-06-16T14:44:33","guid":{"rendered":"https:\/\/flcube.com\/?p=68340"},"modified":"2026-06-16T22:44:35","modified_gmt":"2026-06-16T14:44:35","slug":"hinova-pharmaceuticals-reports-positive-phase-iia-data-for-hp515-in-mash-thr-%ce%b2-agonist-achieves-50-liver-fat-reduction","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68340","title":{"rendered":"Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH \u2013 THR-\u03b2 Agonist Achieves >50% Liver Fat Reduction"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hinova Pharmaceuticals Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688302:SHA\">SHA: 688302<\/a>) announced that <strong>final analysis results<\/strong> from the <strong>Phase IIa clinical trial<\/strong> of <strong>HP515<\/strong>, a Class 1 innovative drug independently developed by the company for the treatment of <strong>metabolic dysfunction-associated steatohepatitis (MASH)<\/strong>, have <strong>met the primary endpoint and key secondary endpoints<\/strong> with high statistical significance.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-overview\" class=\"wp-block-heading\">Clinical Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>HP515 \u2013 oral, highly selective THR-\u03b2 agonist<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Hinova Pharmaceuticals Inc. (SHA: 688302)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Metabolic dysfunction-associated steatohepatitis (MASH)<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Phase IIa, randomized, placebo-controlled<\/td><\/tr><tr><td><strong>Treatment Duration<\/strong><\/td><td>12 weeks, once-daily oral administration<\/td><\/tr><tr><td><strong>Dose Groups<\/strong><\/td><td>40 mg, 50 mg, 60 mg<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-primary-endpoint-results-liver-fat-content-reduction\" class=\"wp-block-heading\">Primary Endpoint Results \u2013 Liver Fat Content Reduction<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Group<\/th><th>Mean LFC Reduction at 12 Weeks<\/th><th>p-value vs Placebo<\/th><\/tr><\/thead><tbody><tr><td><strong>Placebo<\/strong><\/td><td>3.5%<\/td><td>Reference<\/td><\/tr><tr><td><strong>HP515 40 mg<\/strong><\/td><td>&gt;50%<\/td><td>&lt;0.001<\/td><\/tr><tr><td><strong>HP515 50 mg<\/strong><\/td><td>&gt;50%<\/td><td>&lt;0.001<\/td><\/tr><tr><td><strong>HP515 60 mg<\/strong><\/td><td>&gt;50%<\/td><td>&lt;0.001<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">All three active dose groups achieved <strong>statistically significant liver fat content (LFC) reductions exceeding 50%<\/strong>, compared to only 3.5% in the placebo group (P&lt;0.001).<\/p>\n\n\n\n<h2 id=\"h-secondary-endpoint-results\" class=\"wp-block-heading\">Secondary Endpoint Results<\/h2>\n\n\n\n<h3 id=\"h-lfc-response-rates\" class=\"wp-block-heading\">LFC Response Rates<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>\u226530% LFC reduction:<\/strong> Significantly higher proportions in all active dose groups vs placebo (P&lt;0.001)<\/li>\n\n\n\n<li><strong>\u226550% LFC reduction:<\/strong> Significantly higher proportions in all active dose groups vs placebo (P&lt;0.001)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-lipid-profile-improvements-p-lt-0-001-for-all-comparisons\" class=\"wp-block-heading\">Lipid Profile Improvements (P&lt;0.001 for all comparisons)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Low-density lipoprotein cholesterol (LDL-C):<\/strong> Significant reduction<\/li>\n\n\n\n<li><strong>Apolipoprotein B (ApoB):<\/strong> Significant reduction<\/li>\n\n\n\n<li><strong>Non-high-density lipoprotein cholesterol (nonHDL-C):<\/strong> Significant reduction<\/li>\n\n\n\n<li><strong>Total cholesterol (TC):<\/strong> Significant reduction<\/li>\n\n\n\n<li><strong>Triglycerides (TG):<\/strong> Significant reduction<\/li>\n\n\n\n<li><strong>Small dense LDL-C (sd-LDL-C):<\/strong> Significant reduction<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-mechanism-of-action-amp-innovation\" class=\"wp-block-heading\">Mechanism of Action &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> Thyroid hormone receptor beta subtype (THR-\u03b2)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Highly selective and potent THR-\u03b2 agonist that directly activates downstream gene transcription<\/li>\n\n\n\n<li><strong>Therapeutic Effects:<\/strong><\/li>\n\n\n\n<li>Enhances hepatocyte lipid metabolism activity<\/li>\n\n\n\n<li>Increases hepatic fat metabolism<\/li>\n\n\n\n<li>Reduces lipotoxicity<\/li>\n\n\n\n<li><strong>Classification:<\/strong> Class 1 innovative drug (first-in-class in China)<\/li>\n\n\n\n<li><strong>Market Status:<\/strong> No THR-\u03b2 targeting product approved for marketing in China as of announcement date<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-significance\" class=\"wp-block-heading\">Market Impact &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MASH Market Opportunity:<\/strong> Global MASH\/NASH therapeutics market projected to reach <strong>USD 40+ billion by 2030<\/strong>, representing one of the largest unmet medical needs in hepatology<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Multiple companies pursuing THR-\u03b2 agonists globally, including Madrigal&#8217;s resmetirom (approved in US); HP515 represents China&#8217;s first domestically developed candidate in this class<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Dual benefit of significant liver fat reduction coupled with comprehensive lipid profile improvements addresses both hepatic and cardiovascular risk factors<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> If approved, HP515 would fill a critical gap in China&#8217;s MASH treatment landscape and position Hinova as a leader in metabolic liver disease therapeutics<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The robust Phase IIa data support rapid advancement to Phase III development, with all three dose levels demonstrating compelling efficacy and establishing a clear dose-response relationship.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations for HP515. Actual results may differ due to risks including Phase III trial outcomes, regulatory decisions, competitive dynamics, and execution of Hinova&#8217;s development strategy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688302_20260616_255I.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688302_20260616_255I.\"><\/object><a id=\"wp-block-file--media-245b1fa9-7499-4855-9408-c4d9dd62bbc4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688302_20260616_255I.pdf\">688302_20260616_255I<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688302_20260616_255I.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-245b1fa9-7499-4855-9408-c4d9dd62bbc4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hinova Pharmaceuticals Inc. (SHA: 688302) announced that final analysis results from the Phase IIa clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,331,76,1140],"class_list":["post-68340","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hinova-pharmaceuticals","tag-nash","tag-sha-688302"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH \u2013 THR-\u03b2 Agonist Achieves &gt;50% Liver Fat Reduction - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hinova Pharmaceuticals Inc. (SHA: 688302) announced that final analysis results from the Phase IIa clinical trial of HP515, a Class 1 innovative drug independently developed by the company for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), have met the primary endpoint and key secondary endpoints with high statistical significance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68340\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH \u2013 THR-\u03b2 Agonist Achieves &gt;50% Liver Fat Reduction\" \/>\n<meta property=\"og:description\" content=\"Hinova Pharmaceuticals Inc. (SHA: 688302) announced that final analysis results from the Phase IIa clinical trial of HP515, a Class 1 innovative drug independently developed by the company for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), have met the primary endpoint and key secondary endpoints with high statistical significance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68340\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T14:44:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-16T14:44:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68340#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68340\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH \u2013 THR-\u03b2 Agonist Achieves >50% Liver Fat Reduction\",\"datePublished\":\"2026-06-16T14:44:33+00:00\",\"dateModified\":\"2026-06-16T14:44:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68340\"},\"wordCount\":468,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Hinova Pharmaceuticals\",\"NASH\",\"SHA: 688302\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68340#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68340\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68340\",\"name\":\"Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH \u2013 THR-\u03b2 Agonist Achieves >50% Liver Fat Reduction - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-16T14:44:33+00:00\",\"dateModified\":\"2026-06-16T14:44:35+00:00\",\"description\":\"Hinova Pharmaceuticals Inc. (SHA: 688302) announced that final analysis results from the Phase IIa clinical trial of HP515, a Class 1 innovative drug independently developed by the company for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), have met the primary endpoint and key secondary endpoints with high statistical significance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68340#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68340\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68340#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH \u2013 THR-\u03b2 Agonist Achieves >50% Liver Fat Reduction\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH \u2013 THR-\u03b2 Agonist Achieves >50% Liver Fat Reduction - Insight, China&#039;s Pharmaceutical Industry","description":"Hinova Pharmaceuticals Inc. (SHA: 688302) announced that final analysis results from the Phase IIa clinical trial of HP515, a Class 1 innovative drug independently developed by the company for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), have met the primary endpoint and key secondary endpoints with high statistical significance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68340","og_locale":"en_US","og_type":"article","og_title":"Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH \u2013 THR-\u03b2 Agonist Achieves >50% Liver Fat Reduction","og_description":"Hinova Pharmaceuticals Inc. (SHA: 688302) announced that final analysis results from the Phase IIa clinical trial of HP515, a Class 1 innovative drug independently developed by the company for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), have met the primary endpoint and key secondary endpoints with high statistical significance.","og_url":"https:\/\/flcube.com\/?p=68340","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-16T14:44:33+00:00","article_modified_time":"2026-06-16T14:44:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68340#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68340"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH \u2013 THR-\u03b2 Agonist Achieves >50% Liver Fat Reduction","datePublished":"2026-06-16T14:44:33+00:00","dateModified":"2026-06-16T14:44:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68340"},"wordCount":468,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Hinova Pharmaceuticals","NASH","SHA: 688302"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68340#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68340","url":"https:\/\/flcube.com\/?p=68340","name":"Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH \u2013 THR-\u03b2 Agonist Achieves >50% Liver Fat Reduction - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-16T14:44:33+00:00","dateModified":"2026-06-16T14:44:35+00:00","description":"Hinova Pharmaceuticals Inc. (SHA: 688302) announced that final analysis results from the Phase IIa clinical trial of HP515, a Class 1 innovative drug independently developed by the company for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), have met the primary endpoint and key secondary endpoints with high statistical significance.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68340#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68340"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68340#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH \u2013 THR-\u03b2 Agonist Achieves >50% Liver Fat Reduction"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68340"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68340\/revisions"}],"predecessor-version":[{"id":68342,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68340\/revisions\/68342"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}